What is Melanotan II?
Melanotan II (MT-II) is a synthetic cyclic heptapeptide designed as a potent, non-selective agonist of the melanocortin receptor family. It was developed at the University of Arizona in the 1980s and early 1990s by researchers including Victor Hruby and colleagues, who were originally working to create an analog of alpha-melanocyte-stimulating hormone (α-MSH) that would be metabolically stable and sufficiently potent to be therapeutically useful for photoprotection of the skin without ultraviolet exposure. The founding concept was elegant and straightforward: melanin — the dark pigment produced by melanocytes in response to UV radiation — absorbs UV photons and dissipates their energy as heat, providing a physical shield against DNA-damaging radiation. If a pharmacological agent could drive melanin production independent of UV exposure, it might reduce skin cancer risk while providing the cosmetic tanning effect that many people seek through sun exposure.
The specific chemical structure of Melanotan II reflects the molecular engineering required to achieve metabolic stability. Native α-MSH is a linear tridecapeptide (13 amino acids) that is rapidly degraded by circulating and tissue proteases, with a half-life measured in minutes. By cyclizing the peptide (forming an intramolecular disulfide-like ring), incorporating a D-phenylalanine in place of a natural L-phenylalanine at a key position, and truncating the sequence to the core active heptapeptide (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2), the University of Arizona team created a compound with dramatically improved receptor binding affinity, metabolic stability, and potency compared to native α-MSH. The acetylated N-terminus and amidated C-terminus further contribute to stability.
What was not fully appreciated in the early development phase was how dramatically non-selective Melanotan II would prove to be across the melanocortin receptor family. Humans express five melanocortin receptor subtypes (MC1R through MC5R), and while the original tanning motivation targeted MC1R specifically, Melanotan II activates all five subtypes with varying but substantial affinity. MC4R activation drives the sexual arousal and appetite suppression effects that became the compound’s most discussed (and in some circles most sought-after) properties. MC3R engagement contributes to energy balance effects. This non-selectivity has defined both the compound’s broad pharmacological effects and its complex safety profile. Melanotan II has never received FDA approval for any indication and remains an investigational compound.
For context on where Melanotan II sits relative to other melanocortin-targeting compounds and peptides with overlapping mechanisms, the Peptide Database includes entries on PT-141 (bremelanotide), which is the MC4R-selective derivative of Melanotan II that received FDA approval for hypoactive sexual desire disorder. The AI Coach can provide comparative analysis across melanocortin-targeting compounds.
Research Benefits
- UV-independent melanogenesis: Melanotan II drives melanin production through MC1R activation without requiring UV radiation, producing cosmetic tanning and theoretical photoprotection through a pharmacological mechanism rather than UV-induced DNA damage.
- Enhanced sexual arousal and erectile function: MC4R activation produces robust pro-erectile and pro-libido effects in both preclinical and human studies, representing the pharmacological basis for the FDA-approved bremelanotide (PT-141) derivative.
- Appetite suppression: MC4R and MC3R activation through central melanocortin pathways in the hypothalamus reduces food intake in animal models and produces subjectively reduced appetite in human users, aligning with the established role of the melanocortin system in energy homeostasis.
- Reduced UV exposure required for maintained pigmentation: In research settings, Melanotan II has been shown to significantly reduce the cumulative UV dose required to achieve and maintain a given level of skin pigmentation, which from a theoretical skin protection standpoint could reduce mutagenic UV load.
- Melanocortin system research tool: As a potent pan-melanocortin agonist, Melanotan II has been an important pharmacological research tool for characterizing the distinct physiological roles of each melanocortin receptor subtype, contributing to the development of selective agonists and antagonists.
- Potential autoimmune skin condition applications: Some research has explored melanocortin system activation in inflammatory skin conditions, as MC1R and MC3R activation can modulate innate immune responses in keratinocytes and other skin cells — though this area remains early-stage.
- Compounding evidence for energy expenditure effects: Beyond appetite suppression, melanocortin receptor activation has been associated with increased energy expenditure in animal studies, contributing to the overall negative energy balance observed with MC4R agonism.
How Melanotan II Works
MC1R Activation: Melanogenesis via Tyrosinase and cAMP
The original intended mechanism of Melanotan II — and the one that aligns most directly with the compound’s development rationale — is activation of MC1R on melanocytes in the skin to drive melanin production independent of UV exposure. Under normal physiological conditions, UV radiation damages epidermal keratinocyte DNA, which triggers p53 activation and subsequent secretion of α-MSH and ACTH from keratinocytes. These melanocortin peptides diffuse to adjacent melanocytes and bind MC1R, initiating the signaling cascade that drives melanogenesis.
When Melanotan II activates MC1R, it engages the same downstream pathway through Gs-coupled cAMP elevation. Increased intracellular cAMP activates protein kinase A (PKA), which phosphorylates the transcription factor CREB. Activated CREB drives expression of MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte differentiation and melanogenesis. MITF, in turn, activates transcription of the genes encoding the three key melanogenic enzymes: tyrosinase (the rate-limiting enzyme), tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (DCT/TYRP2). Tyrosinase hydroxylates L-tyrosine to DOPA and then oxidizes DOPA to dopaquinone, initiating the biosynthetic cascade that ultimately produces eumelanin (brown/black) or phaeomelanin (yellow/red) depending on the cysteine availability and subsequent biochemical routing.
Melanotan II activates MC1R without requiring UV-induced DNA damage as the upstream trigger. From a cosmetic standpoint, this produces skin darkening. From a theoretical photoprotection standpoint, the generated melanin can absorb UV radiation, but importantly, Melanotan II-driven melanin production may differ in its photoprotective quality from UV-induced melanin — the UV tanning response includes both melanogenesis and dispersion of melanin into a supranuclear cap over keratinocyte nuclei, a protective geometry that pharmacological tanning may not fully replicate. This nuance is important for understanding the limits of the photoprotection rationale.
MC4R: Appetite Suppression and Sexual Arousal Pathways
MC4R is expressed abundantly in the central nervous system, particularly in the hypothalamus — specifically in the paraventricular nucleus (PVN), the dorsomedial hypothalamus, and the lateral hypothalamus. These regions are central to the regulation of food intake, energy balance, and autonomic function. In the hypothalamic melanocortin circuit, MC4R activation by endogenous α-MSH produced by POMC neurons drives anorexigenic (appetite-suppressing) signaling, opposing the orexigenic signals produced by AgRP/NPY neurons that antagonize MC4R. Melanotan II’s potent MC4R agonism therefore produces robust appetite suppression by activating the same anorexigenic pathway that endogenous melanocortins use — but with higher potency and longer duration than native α-MSH.
The sexual arousal effects of Melanotan II are also primarily MC4R-mediated. MC4R is expressed in lumbosacral spinal cord neurons that project to the corpus cavernosum and are involved in the coordination of penile erection. MC4R is also expressed in regions of the brain involved in sexual motivation and arousal. MC4R activation promotes erection through both spinal and supraspinal mechanisms — at the spinal level by potentiating the parasympathetic outflow that drives penile blood flow, and at the supraspinal level by increasing sexual motivation. This is the mechanism that the FDA-approved derivative PT-141 (bremelanotide) exploits — but with greater MC4R selectivity than Melanotan II, reducing off-target effects. In women, MC4R activation by Melanotan II and PT-141 similarly increases genital blood flow and subjective sexual desire, with effects that appear to be genuinely central (brain-level) rather than purely vascular — an important distinction from PDE5 inhibitors like sildenafil, which work peripherally.
MC3R: Energy Balance and Anti-Inflammatory Contributions
MC3R plays a somewhat different role in the melanocortin system than MC1R and MC4R. It is expressed in the hypothalamus and limbic system, with particularly high expression in the arcuate nucleus, and functions as an autoreceptor on POMC neurons — providing feedback regulation that modulates the overall sensitivity of the melanocortin system. MC3R also influences energy partitioning in a manner distinct from MC4R’s purely anorexigenic effect: while MC4R primarily reduces food intake, MC3R appears to regulate how the body distributes available energy between adipose storage and active metabolism. MC3R knockout mice develop obesity even at normal caloric intake, suggesting that MC3R activation supports metabolic flexibility and appropriate fat mobilization.
MC3R is also expressed on immune cells including macrophages and T lymphocytes, where its activation produces anti-inflammatory effects — reducing production of pro-inflammatory cytokines including TNF-α and IL-6 in stimulated immune cells. This anti-inflammatory dimension of MC3R activity may contribute to some of the broader physiological effects observed with pan-melanocortin agonists like Melanotan II, though the specific contribution of MC3R vs. other receptor subtypes to these systemic effects is difficult to disentangle without receptor-selective compounds. MC5R, the fifth melanocortin receptor subtype, is expressed in exocrine glands including the lacrimal gland, preputial gland, and sebaceous glands, and appears to regulate exocrine secretory function — its activation by Melanotan II likely contributes to the changes in sebum production and related skin effects some users report.
Research Findings
UV-Free Tanning and Photoprotection Research
The University of Arizona group conducted several human studies of Melanotan II during the 1990s and early 2000s, including what appears to have been the first controlled human pharmacology study of the compound. In these initial trials, subjects received low-dose subcutaneous Melanotan II and were evaluated for pigmentation response, safety, and pharmacodynamics. The studies demonstrated that Melanotan II could indeed produce measurable increases in skin pigmentation independent of UV exposure in fair-skinned subjects, validating the fundamental proof-of-concept. Pigmentation was most pronounced in individuals with Fitzpatrick skin types I and II (fair skin, most susceptible to UV damage), the population for whom photoprotection would theoretically be most valuable.
However, the clinical development program for Melanotan II as a photoprotection agent was never advanced to phase 3 trials or regulatory approval. The reasons include the compound’s non-selectivity — the side effects driven by MC4R activation (nausea, spontaneous erections, facial flushing) at doses sufficient to drive meaningful melanogenesis were considered unacceptable for a cosmetic or preventive health indication where the risk-benefit calculation is different from a life-threatening disease context. Subsequent research therefore bifurcated: the sexual function application was pursued through the more selective PT-141 (bremelanotide), and the photoprotection application largely stalled at the clinical level, though preclinical research into MC1R-selective agonists for tanning and photoprotection continued.
Sexual Function and Libido Studies
The pro-erectile and pro-libido effects of Melanotan II were documented in both animal models and the University of Arizona human pharmacology studies. In the preclinical literature, Melanotan II reliably induces erections in rodent models and yawning behavior (a recognized behavioral correlate of central MC4R activation), with effects blocked by MC4R-selective antagonists. In human studies, the Arizona group reported that a substantial proportion of male subjects in Melanotan II trials experienced spontaneous erections at doses used for tanning studies — an unexpected finding that dramatically redirected the research program’s focus.
This observation led directly to the development of bremelanotide (PT-141), a cyclic peptide derivative of Melanotan II with improved receptor selectivity, which ultimately received FDA approval in 2019 under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. The approval of bremelanotide is significant for the Melanotan II story because it represents regulatory validation that the MC4R-mediated sexual function mechanism is clinically meaningful and pharmacologically exploitable — essentially confirming that the mechanism Melanotan II uses is real and therapeutically significant, even if Melanotan II itself has never been approved due to its unfavorable non-selectivity profile.
Appetite Suppression and Weight-Related Effects
The appetite-suppressing effects of Melanotan II, driven by central MC4R and MC3R agonism, have been consistently observed in animal models and documented anecdotally by human users. In rodents, Melanotan II administered peripherally or centrally produces dose-dependent reductions in food intake, increased energy expenditure, and — with sustained dosing — reduction in body weight and fat mass, even in diet-induced obese animals. The central melanocortin system is now well-established as a critical regulator of body weight homeostasis, and Melanotan II’s effects in animal models contributed to the foundational understanding of how MC4R agonism could in principle serve as an anti-obesity therapeutic mechanism.
The appetite suppression observed with Melanotan II has not been developed into a viable clinical application, for the same reasons that prevented its tanning application from reaching regulatory approval — the nausea and other non-MC4R-mediated side effects at weight-loss-relevant doses create an unacceptable tolerability profile. The field has instead pursued MC4R-selective agonists (setmelanotide, which is approved for MC4R pathway obesity due to loss-of-function mutations in POMC or LEPR) as the appropriate development path for melanocortin-targeted obesity treatment.
Mole and Melanocytic Lesion Monitoring Concerns
One of the most clinically important considerations for anyone researching Melanotan II is its effect on existing melanocytic lesions. The same MC1R-driven melanogenesis that causes general skin darkening can stimulate existing nevi (moles) to darken and potentially enlarge. In the dermatological context, changes in the size, color, or regularity of nevi are primary warning signs of melanoma development. There have been case reports in the published literature linking Melanotan II use with darkening of pre-existing nevi, development of new nevi, and in some cases melanoma — though establishing causation versus correlation in these case reports is difficult given the confounding factors involved (many users are also seeking tanning via UV exposure).
The theoretical concern is genuine and mechanistically plausible: MC1R activation drives melanocyte proliferation and melanin production, and these same pathways are dysregulated in melanoma. While there is no definitive evidence that Melanotan II causes melanoma in individuals who would not otherwise develop it, the biologically plausible stimulatory effect on existing melanocytic cells — particularly in individuals with many nevi, atypical mole syndrome, or a personal or family history of melanoma — represents a significant concern that the dermatological literature has highlighted consistently. Anyone who has been a Melanotan II user, or who encounters individuals who have used it, should be aware that full-body skin examination with particular attention to nevi changes is medically appropriate.
Comparative Analysis: Melanotan II vs. Bremelanotide (PT-141)
Understanding the relationship between Melanotan II and its derivative bremelanotide is important context for anyone researching the melanocortin agonist space. Bremelanotide was specifically engineered to address the non-selectivity issues that prevented Melanotan II from reaching regulatory approval. While both are cyclic peptides derived from the same core α-MSH pharmacophore, bremelanotide has been optimized for improved MC4R selectivity and a reduced MC1R activation profile, which substantially attenuates the tanning effect while preserving the sexual arousal and desire-enhancing mechanisms. The FDA’s approval of bremelanotide for HSDD in women validates the underlying mechanism while confirming that the field considers Melanotan II’s promiscuous receptor activity an unresolved safety liability. Melanotan II remains unapproved for any indication and is not commercially available through legal pharmaceutical channels in most jurisdictions.
Dosage and Administration
Doses Used in Research Studies
The University of Arizona human studies used doses ranging from approximately 0.01 to 0.10 mg/kg by subcutaneous injection. At the lower end of this range, doses of approximately 0.025 mg/kg produced detectable pigmentation changes with modest side effects in some participants. At 0.1 mg/kg, robust pigmentation responses were observed but side effects — particularly nausea and spontaneous erections in male subjects — were substantially more common and pronounced. Translating these weight-based doses to absolute doses gives ranges from roughly 1 to 7 mg for an average adult, consistent with the doses that became referenced in online communities following the Arizona trials. However, it is critical to understand that these doses were established in supervised clinical settings with careful monitoring — the safety data from these studies should not be interpreted as endorsement for unsupervised use at these dose levels. Use the Peptide Calculator for any reconstitution math, but be aware that the dosing information from research settings carries substantial uncertainty when extrapolated to unmonitored use.
Route and Injection Site
All research use of Melanotan II has involved subcutaneous injection. There is no approved oral formulation, and oral administration is not pharmacologically viable given that Melanotan II is a peptide that would be substantially degraded in the gastrointestinal tract before reaching systemic circulation. The cyclic structure and D-amino acid substitution provide some metabolic stability compared to native α-MSH, but not sufficient for meaningful oral bioavailability. Subcutaneous injection into abdominal fat is the standard route, with the same general injection practices that apply to other subcutaneous peptides: proper skin preparation, appropriate needle gauge and length for subcutaneous depth, and site rotation.
Timing and Cycle Considerations
In the research literature, Melanotan II’s effects on pigmentation develop over weeks of dosing, reflecting the time required for melanogenesis and melanin accumulation in skin. A loading period followed by a maintenance phase has been the common structure in informal use literature — daily injections during an initial period, followed by reduced frequency to maintain achieved pigmentation. The acute effects (nausea, flushing, sexual arousal) occur within 30–60 minutes of injection and typically last several hours. There is no formally established or clinically validated dosing cycle for Melanotan II, as it has never progressed through the phase 3 clinical development process that would define approved dosing protocols. The lack of an approved clinical protocol is itself significant information about the compound’s regulatory status.
Regulatory and Research Status
Melanotan II has never received FDA approval or approval from any major international regulatory agency for any indication. It is not legally available as a pharmaceutical product in the United States, European Union, UK, Australia, or most other major jurisdictions. In the research peptide market, it is sold for laboratory research purposes only. Its use in human subjects outside of a formally approved clinical trial is off-label, unregulated, and unsupported by an approved safety and efficacy dossier. Unlike bremelanotide (which followed through the full regulatory approval process), Melanotan II’s human use is exclusively driven by its informal distribution as a research compound. This regulatory context is essential to understand when evaluating the risk-benefit profile — there is no FDA-reviewed safety data package, no approved manufacture specification, and no regulatory quality standard that applies to Melanotan II obtained through research markets.
Safety and Side Effects
Acute Side Effects
The acute side effects of Melanotan II are among the most consistently documented aspects of the compound’s pharmacology and directly reflect its non-selective receptor activation. Nausea — sometimes severe — is the most commonly reported acute effect, occurring in a large proportion of users at doses sufficient to drive meaningful melanogenesis. The nausea appears to be mediated primarily through central melanocortin receptors in the brainstem (area postrema) rather than through peripheral GI effects, which explains why it can be intense even with subcutaneous rather than IV administration. Facial flushing, warmth, and lightheadedness occur in many users and are transient. Spontaneous erections — entirely independent of sexual stimulation — are commonly reported by male users within 30–90 minutes of injection. Some users report pronounced yawning, which is a recognized central MC4R activation behavioral response. Fatigue or sedation in the hours following injection has also been reported. These side effects tend to attenuate with repeated dosing as tolerance develops, but they can be significant and distressing, particularly with initial doses.
Melanocytic Lesion and Skin Safety Concerns
As discussed in the Research Findings section, the potential for Melanotan II to stimulate changes in existing melanocytic nevi is the most clinically significant safety concern from a dermatological standpoint. Case reports in the medical literature have documented nevi changes, multiple new nevi development, and melanoma in individuals using Melanotan II. The mechanistic plausibility of these associations — MC1R-driven melanocyte stimulation acting on pre-existing atypical cells — means they cannot be dismissed as coincidental. Dermatologists have published guidelines recommending full-body skin examination for individuals who report Melanotan II use, with particular attention to nevi documenting any changes in size, shape, color, or border irregularity. Individuals with a personal or family history of melanoma, atypical mole syndrome, many nevi, or fair skin (Fitzpatrick I-II) who are the apparent primary target users of Melanotan II for tanning are precisely the individuals at highest baseline risk for melanocyte-related pathology and most likely to be harmed by unsupervised melanocortinergic stimulation.
Cardiovascular and Systemic Concerns
Hypertension is a documented effect of melanocortin receptor agonism, mediated through MC4R-driven sympathetic nervous system activation. In the clinical program for bremelanotide (PT-141), transient blood pressure elevation was sufficiently concerning to exclude the intranasal formulation and inform the dosing and contraindications of the approved subcutaneous bremelanotide product. Melanotan II’s more potent and less selective receptor activation would be expected to produce comparable or more pronounced cardiovascular effects. Individuals with hypertension, cardiovascular disease, or cardiac arrhythmias should be aware that melanocortin agonism has demonstrable hemodynamic effects that represent a genuine safety consideration. Additional reported effects include stretching and yawning spells, changes in mole appearance, injection site reactions, and potential immunological responses to the foreign peptide structure in some users. The absence of long-term controlled safety data means that the full profile of risks associated with repeated Melanotan II use over months or years is genuinely unknown.
Frequently Asked Questions
No. Melanotan I (afamelanotide) is a linear α-MSH analog with greater MC1R selectivity than Melanotan II. It was developed in parallel at the University of Arizona but pursued a different clinical path. Afamelanotide received European Medicines Agency (EMA) approval in 2014 under the brand name Scenesse for the prevention of phototoxicity in adults with erythropoietic protoporphyria — a rare genetic condition in which patients cannot safely tolerate any sun exposure due to a defect in heme biosynthesis. Melanotan II, in contrast, is the cyclic heptapeptide with pan-melanocortin activity and has never received any regulatory approval. The two compounds are often confused in non-specialist discussions, but they are chemically distinct, have substantially different receptor selectivity profiles, and have entirely different regulatory histories.
Melanotan II is not approved by the FDA for any indication and is not legally available as a pharmaceutical product in the United States. The legal status varies by jurisdiction, but in most countries with regulatory frameworks for pharmaceutical products, selling Melanotan II as a drug or therapeutic product for human use would violate pharmaceutical regulations. It exists in a legal gray area as a research compound in some jurisdictions. The FDA has issued warning letters to companies marketing Melanotan II products. Individuals researching its use should be aware of their local regulatory context and the absence of regulatory safety review for any Melanotan II product available through current channels.
PT-141 (bremelanotide) is a derivative of Melanotan II that was specifically developed to optimize for MC4R activity and reduce the MC1R-driven tanning effects and nausea that characterized Melanotan II. Bremelanotide received FDA approval in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women — making it the first centrally acting pharmacological treatment approved for HSDD. Because bremelanotide is approved and manufactured to pharmaceutical standards, it has a defined safety profile, quality assurance, and regulatory oversight that Melanotan II lacks. From a mechanism standpoint, bremelanotide’s primary effects are through MC4R for sexual arousal, with less MC1R activation and therefore less tanning and less nausea compared to Melanotan II at equivalent sexual function-relevant doses.
This is a nuanced question. Melanin produced through Melanotan II-driven MC1R activation does absorb UV radiation and could theoretically provide some degree of photoprotection. However, the photoprotective effect of pharmacologically induced tanning may be less robust than natural UV-induced tanning because the full UV tanning response involves not just melanin production but also upward migration and nuclear capping of melanin granules in keratinocytes — a protective arrangement that may not be fully recapitulated by pharmacological melanogenesis alone. More significantly, the potential for Melanotan II to stimulate pre-existing melanocytic lesions, and the lack of controlled human data demonstrating a net reduction in UV-induced DNA damage or skin cancer incidence, means that claiming skin cancer protection as a practical outcome of Melanotan II use would substantially overstep the available evidence. The original photoprotection research rationale remains intellectually interesting, but it has not been validated through the clinical endpoints that would matter most.
The University of Arizona program produced initial human pharmacology data on both Melanotan I and Melanotan II in the 1990s. Melanotan I (afamelanotide) was licensed to an Australian company (later Scenesse’s developer) and eventually achieved EMA approval for the specific niche indication of erythropoietic protoporphyria. The Melanotan II program did not advance through formal clinical development under institutional sponsorship — the combination of the compound’s non-selectivity, the robust sexual side effects, and the practical challenges of commercializing a tanning compound through regulatory channels led to the program’s clinical stagnation. The compound then entered the informal research peptide market, where it has been distributed and used outside any clinical trial framework, generating the anecdotal literature and case reports that now constitute most of the real-world human experience with the compound.
There is no definitive evidence from controlled studies that Melanotan II causes melanoma. However, there are published case reports of melanoma development in individuals using Melanotan II, and the mechanistic basis for concern — MC1R-driven stimulation of melanocyte proliferation and activity, potentially promoting growth of pre-existing atypical cells — is scientifically plausible. The absence of proof that it causes melanoma does not constitute evidence that it is safe in this regard, particularly given the lack of controlled long-term human safety studies. Dermatologists generally advise that individuals with risk factors for melanoma (numerous nevi, atypical mole syndrome, family history, fair skin) should be especially cautious, and that any Melanotan II use should be accompanied by regular full-body skin examination with dermatological evaluation of any nevi changes.
Melanotan II produces actual biological tanning — real melanin produced by melanocytes — whereas commercial self-tanners using DHA (dihydroxyacetone) work by chemically reacting with dead skin cells in the stratum corneum to produce a brown color without any melanin production or melanocyte activation. DHA-based tanning provides no photoprotection, whereas melanin-based tanning provides some. From a visual appearance standpoint, Melanotan II produces a tan that behaves like natural tanning — it develops gradually, is relatively consistent across the body, and fades as skin cells turn over. DHA tans can be more immediately visible but are superficial. However, the pharmacological risks of Melanotan II versus the zero pharmacological risk of topical DHA application represent an enormous practical difference in risk-benefit for most individuals considering tanning options.
The Peptide Database includes detailed entries on GHK-Cu (skin and wound healing), growth hormone secretagogues with body composition effects, and other compounds with appearance-relevant research. The AI Coach can help contextualize how different compounds compare across mechanisms and safety profiles. For anyone working with injectable peptides of any type, the Peptide Calculator provides essential reconstitution and dosing tools.
References
- Dorr RT, et al. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sciences. 1996;58(20):1777–1784. PubMed
- Wessells H, et al. “Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction.” Urology. 2000;56(4):641–646. PubMed
- Mountjoy KG. “Distribution and function of melanocortin receptors within the brain.” Advances in Experimental Medicine and Biology. 2010;681:29–48. PubMed
- Hadley ME, Dorr RT. “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides. 2006;27(4):921–930. PubMed
- Cummings DE, Overduin J. “Gastrointestinal regulation of food intake.” Journal of Clinical Investigation. 2007;117(1):13–23. PubMed
- Fitzgerald LM, et al. “Melanotan II and melanoma: a case series and review of the literature.” British Journal of Dermatology. 2012;166:1303–1307. PubMed
- Shadiack AM, et al. “Melanocortins in the treatment of male and female sexual dysfunction.” Current Topics in Medicinal Chemistry. 2007;7(11):1137–1144. PubMed
- Lam CW, et al. “Atypical melanocytic lesions following use of Melanotan-II.” Journal of the American Academy of Dermatology. 2014;71(2):e49–e50. PubMed
- Clayton RN. “Bremelanotide (PT-141) — a review of its pharmacology and clinical studies.” Endocrinology. 2021. PubMed